6-(5-((2S)-1,4-dioxan-2-ylmethyl)-1,2,4-oxadiazol-3-yl)-N-(4-fluoro-3-methoxybenzyl)-2-methyl-pyrimidine-4-carboxamide | 1112171-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(5-((2S)-1,4-dioxan-2-ylmethyl)-1,2,4-oxadiazol-3-yl)-N-(4-fluoro-3-methoxybenzyl)-2-methyl-pyrimidine-4-carboxamide
• 英文别名: 6-[5-[[(2S)-1,4-dioxan-2-yl]methyl]-1,2,4-oxadiazol-3-yl]-N-[(4-fluoro-3-methoxyphenyl)methyl]-2-methylpyrimidine-4-carboxamide
• CAS: 1112171-06-8
• 化学式: C₂₁H₂₂FN₅O₅
• 分子量: 443.435
• InChiKey: CNQFJZMLNLJUPC-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS
  申请人：Pfizer Inc.

  公开号：EP2185537A1

  公开（公告）日：2010-05-19
• [EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION PHARMACEUTIQUE ET LEURS COMPOSITIONS
  申请人：PFIZER

  公开号：WO2009016498A1

  公开（公告）日：2009-02-05

  The prsent invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.